US 12,606,620 B2Granted

Anti-LILRB1 antibody and uses thereof

AssigneeLG Chem, Ltd.

InventorsYoon Aa Choi, Han Byul Kim, Shinyoung Kang, Jung A Kim, Heehang Kim, Minsoon Kim, Junhaeng Cho

Life of this patent

Estimating the term…

Abstract

The present invention relates to an anti-LILRB1 antibody having increased specificity for LILRB1, and to uses thereof. Specifically, an anti-LILRB1 antibody or an antigen-binding fragment thereof, and uses thereof in treating cancer are provided.

Claims17

Dependent claims

An anti-LILRB1 antibody or antigen-binding fragment thereof, comprising:

(1) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
1, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
2, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
3, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
4, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
5, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
6;
(2) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
13, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
14, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
15, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
16, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
17, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
18;
(3) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
25, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
26, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
27, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
28, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
29, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
30;
(4) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
37, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
38, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
39, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
40, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
41, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
42;
(5) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
49, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
50, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
51, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
52, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
53, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
54;
(6) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
61, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
62, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
63, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
64, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
65, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
66;
(7) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
73, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
74, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
75, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
76, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
77, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
78;
(8) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
85, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:86, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
87, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
88, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
89, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
90;
(9) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
97, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
98, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
99, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
100, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
101, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
102;
(10) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
109, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
110, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
111, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
112, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
113, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
114;
(11) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
121, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
122, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
123, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
124, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
125, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
126;
(12) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
133, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
134, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
135, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
136, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
137, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
138;
(13) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
145, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
146, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
147, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
148, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
149, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
150;
(14) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
157, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
158, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
159, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
160, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
161, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
162;
(15) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
169, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
170, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
171, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
172, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
173, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
174;
(16) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
181, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
182, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
183, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
184, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
185, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
186;
(17) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
193, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
194, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
195, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
196, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
197, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
198;
(18) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
205, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
206, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
207, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
208, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
209, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
210;
or
(19) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
217, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
218, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
219, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
220, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
221, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
222.

130 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/003,582Filed 27 Jul 2021
Priority: KR 10-2020-009405328 Jul 2020
Published: US 2023/0374127 A123 Nov 2023
Granted: 21 Apr 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 39/00
Medicinal preparations containing antigens or antibodies
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies

Family

US 2023/0374127 A1Pre-grant publication · published 23 Nov 2023
US 12,606,620 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An anti-LILRB1 antibody or antigen-binding fragment thereof, comprising:

(1) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
1, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
2, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
3, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
4, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
5, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
6;
(2) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
13, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
14, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
15, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
16, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
17, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
18;
(3) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
25, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
26, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
27, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
28, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
29, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
30;
(4) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
37, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
38, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
39, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
40, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
41, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
42;
(5) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
49, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
50, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
51, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
52, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
53, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
54;
(6) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
61, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
62, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
63, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
64, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
65, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
66;
(7) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
73, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
74, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
75, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
76, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
77, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
78;
(8) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
85, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:86, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
87, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
88, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
89, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
90;
(9) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
97, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
98, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
99, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
100, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
101, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
102;
(10) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
109, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
110, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
111, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
112, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
113, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
114;
(11) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
121, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
122, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
123, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
124, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
125, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
126;
(12) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
133, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
134, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
135, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
136, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
137, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
138;
(13) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
145, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
146, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
147, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
148, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
149, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
150;
(14) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
157, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
158, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
159, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
160, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
161, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
162;
(15) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
169, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
170, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
171, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
172, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
173, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
174;
(16) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
181, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
182, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
183, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
184, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
185, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
186;
(17) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
193, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
194, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
195, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
196, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
197, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
198;
(18) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
205, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
206, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
207, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
208, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
209, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
210;
or
(19) the CDR-L1 comprising the amino acid sequence of SEQ ID NO:
217, the CDR-L2 comprising the amino acid sequence of SEQ ID NO:
218, the CDR-L3 comprising the amino acid sequence of SEQ ID NO:
219, the CDR-H1 comprising the amino acid sequence of SEQ ID NO:
220, the CDR-H2 comprising the amino acid sequence of SEQ ID NO:
221, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO:
222.

130 more elements

Facts

Application

18/003,582Filed 27 Jul 2021

Priority

KR 10-2020-009405328 Jul 2020

Published

US 2023/0374127 A123 Nov 2023

Granted

21 Apr 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 39/00
Medicinal preparations containing antigens or antibodies
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies